On the other hand, Fujiwara et al. have described changes in insulin secretion dynamics after initiation of treatment with ICIs in patients who subsequently developed DM-ICIs [38], so that C-peptide monitoring in at-risk patients may be a strategy to consider. Here, INS is linked to diabetes mellitus.